UB-612
COVID-19 Booster
Phase 3Completed
Key Facts
About Vaxxinity
Vaxxinity (NASDAQ: VAXX) is a U.S.-based biotech firm with a mission to democratize healthcare through its proprietary Active Immunotherapy Medicine (AIM) platform. The company has achieved significant validation, including a successful Phase 3 trial for a COVID-19 booster and billions of doses commercialized in animal health, underpinning its strategy to develop long-acting, scalable therapies for large markets like Alzheimer's and hypercholesterolemia. Its core differentiator is the ability to safely break immune tolerance against self-antigens, a key hurdle in chronic disease treatment, using a synthetic, low-cost peptide approach that requires no frozen cold chain.
View full company profile